Global Stem Cell Partnering 2010-2018: Deal trends, players and financials
Trends in stem cell partnering
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for stem cells
The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.
The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 500 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.
Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts provides the reader with the following Key benefits
In-depth understanding of Stem Cell deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Stem Cell agreements with numerous real life case studies
Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
Identify most active Stem Cell dealmakers since 2010
Insight into terms included in a Stem Cell partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.
Stem Cell Partnering Terms and Agreements includes:
Trends in Stem Cell dealmaking in the biopharma industry since 2010
Analysis of Stem Cell deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Stem Cell deals
Access to Stem Cell contract documents
Leading Stem Cell deals by value since 2010
Most active Stem Cell dealmakers since 2010
In GlobalStem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts, the available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Stem Cell Partnering 2010-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 500 Stem Cell deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 Introduction
Chapter 2 Trends in Stem Cell dealmaking
2.2. Stem Cell partnering over the years
2.3. Most active Stem Cell dealmakers
2.4. Stem Cell partnering by deal type
2.5. Stem Cell partnering by therapy area
2.6. Deal terms for Stem Cell partnering
2.6.1 Stem Cell partnering headline values
2.6.2 Stem Cell deal upfront payments7
2.6.3 Stem Cell deal milestone payments
2.6.4 Stem Cell royalty rates
Chapter 3 Leading Stem Cell deals
3.2. Top Stem Cell deals by value
Chapter 4 Most active Stem Cell dealmakers
4.2. Most active Stem Cell dealmakers
4.3. Most active Stem Cell partnering company profiles
Chapter 5 Stem Cell contracts dealmaking directory
5.2. Stem Cell contracts dealmaking directory
Chapter 6 Stem Cell dealmaking by technology type
Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 Stem Cell deals by company A-Z
Appendix 2 Stem Cell deals by stage of development
Appendix 3 Stem Cell deals by deal type
Appendix 4 Stem Cell deals by therapy area
Appendix 5 Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Stem Cell partnering since 2010
Figure 2: Active Stem Cell dealmaking activity since 2010
Figure 3: Stem Cell partnering by deal type since 2010
Figure 4: Stem Cell partnering by disease type since 2010
Figure 5: Stem Cell deals with a headline value
Figure 6: Stem Cell deals with an upfront value
Figure 7: Stem Cell deals with a milestone value
Figure 8: Stem Cell deals with a royalty rate value
Figure 9: Top Stem Cell deals by value since 2010
Figure 10: Most active Stem Cell dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
2019-2023 Global Hepatitis A, B, C, D, E Diagnostics Market: Emerging Opportunities in the US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and NAT Tests, Technology and Instrumentation Review
The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition,View Report
Complete report $8,500. DataPack (test volumes, sales forecasts, supplier shares) $5,500.This new 318-page report from 68 tables and provides analysis of the global drug of abuse testing market, includingView Report
Synthetic Stem Cell Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing onView Report
The Global and Southeast Asia Mesenchymal Stem Cell Industry, 2013-2023 Market Research Report is a professional and in-depth study on the current state of the global Mesenchymal Stem Cell industryView Report
Your are not allow to send sample request
Fill The Form For Sample Request